Use of CAR T-cell Therapy in Earlier Lines in Relapsed Refractory Multiple Myeloma

Panelists discuss how the use of CAR T-cell therapy in earlier lines of treatment for relapsed/refractory multiple myeloma could potentially improve long-term outcomes, considering factors such as patient selection, optimal timing, and the impact on subsequent treatment options.